(lp0
S"A Counter Offer For Receptos Inc From Another Bidder Is Possible: Wedbush Smarter Analyst - Jul 15, 2015 Receptos Inc  shares rose 10 per cent in after-hours trading, following the news that Celgene Corporation  intends to acquire Receptos for $232/share or $7.2 billion net of cash, a premium of 12% to RCPT's July 14th closing&nbsp;...Celgene to Buy Biotech Drugmaker Receptos for $7.2 Billion - BloombergCelgene to Buy Receptos for $7.2 Billion - Wall Street Journal"
p1
aS"Analysts Taking Aim at Receptos, Inc. : Consensus View in Focus Melville Review - 10 hours ago Receptos, Inc. 's stock has been of interest for both individual investors and Wall Street analysts recently."
p2
aS'Receptos Completes Enrollment of RADIANCE Phase 3 Trial of Ozanimod in ... GlobeNewswire  - Apr 1, 2015 SAN DIEGO, April 1, 2015  -- Receptos, Inc.  announced today that the Company has completed enrollment in the RADIANCE Phase 3 trial of ozanimod  in patients with Relapsing Multiple Sclerosis&nbsp;...'
p3
aS"Receptos Inc Can Be Acquired For $348 Per Share: Wedbush Smarter Analyst - Jun 16, 2015 Wedbush analyst Liana Moussatos has high hopes for Receptos Inc , reiterating an Outperform rating on the stock, while increasing the company's acquisition value to $348 .Receptos Insider Sale Defies Logic if Takeout Is Imminent - TheStreet.com"
p4
aS'Class Fee In $7.2B Receptos Merger Suit Slashed To $100K Law360  - Jul 22, 2016 The decision potentially closed out a suit filed in July that challenged the merger of Receptos, a company that focuses on developing new drugs for immune and metabolic diseases, such as ulcerative colitis, with Celgene, a global developer and producer ...'
p5
aS'Receptos Announces Pricing of Initial Public Offering of Common Stock GlobeNewswire  - May 8, 2013 SAN DIEGO, May 8, 2013  -- Receptos, Inc. , a biopharmaceutical company developing therapeutic candidates for the treatment of immune and metabolic diseases, today announced the pricing of its initial public offering&nbsp;...'
p6
aS'Receptos Initiates SUNBEAM Phase 3 Trial of RPC1063 in Relapsing Multiple ... GlobeNewswire  - Dec 22, 2014 SAN DIEGO, Dec. 22, 2014  -- Receptos, Inc.  announced today that the Company has enrolled the first patient in the SUNBEAM Phase 3 trial of RPC1063 in patients with relapsing multiple sclerosis .'
p7
aS"Receptos Investor Sues To Block Celgene's $7.2B Buyout Law360  - Jul 22, 2015 Law360, Wilmington  -- A Receptos Inc. shareholder sued the San Diego biopharmaceutical company and Celgene Corp."
p8
aS'Analysts Provide Insight on Celgene Corporation  And Receptos Inc (RCPT ... Smarter Analyst - Jul 16, 2015 Oncology therapy company Celgene Corporation  announced a definitive agreement on July 14 to acquire Receptos Inc . Under the terms of the agreement, Celgene will pay $7.2 billion in cash for the autoimmune drug&nbsp;...'
p9
aS'Receptos Announces First Patient Treated With Anti-Interleukin-13 Antibody in ... GlobeNewswire  - Oct 3, 2014 SAN DIEGO, Oct. 3, 2014  -- Receptos, Inc. , a biopharmaceutical company developing therapeutic candidates for the treatment of immune and metabolic diseases, today announced that the first patient has been treated&nbsp;...'
p10
a.